IP Verse

Pharmaceutical Composition Containing Crystalline Macitentan - EP2988733

The patent EP2988733 was granted to Sandoz on Mar 27, 2019. The application was originally filed on Apr 17, 2014 under application number EP14721256A. The patent is currently recorded with a legal status of "Revoked".

EP2988733

SANDOZ
Application Number
EP14721256A
Filing Date
Apr 17, 2014
Status
Revoked
Sep 16, 2024
Grant Date
Mar 27, 2019
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

GILL JENNINGS & EVERYDec 23, 2019GILL JENNINGS & EVERYADMISSIBLE

Patent Citations (3) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
INTERNATIONAL-SEARCH-REPORTWO2007031933
OTHEREP2988733
OTHERWO2007031933

Non-Patent Literature (NPL) Citations (13) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
EXAMINATION- Apotex Inc., "Lamivudine tablets, USP - prescribing information", (20171101), URL: www.apotex.com, (20181009), XP055513494-
EXAMINATION- Bilcare, "Bilcare duplex products overview", (20160101), pages 1 - 2, URL: www.bilcare.com, (20181009), XP055513623-
EXAMINATION- Bilcare, "Bilcare triplex blister films product overview", (20160101), pages 1 - 2, URL: www.bilcare.com, (20181009), XP055513593-
EXAMINATION- Deutsche Norm, "DIN 53122-1, Determination of the water vapour transmission rate", DIN 53122-1, Determination of the water vapour transmission rate, (20010801), pages 1 - 7, XP055513614-
EXAMINATION- Martin H Bolli ET AL, "SUPPORTING INFORMATION The Discovery of N-[5-(4-Bromophenyl)-6-[2-[(5-bromo-2- pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N'-propylsulfamide (Macitentan), an Orally Active, Potent Dual Endothelin Receptor Antagonist Contents", Journal of Medicinal Chemistry, (20120913), XP055357422-
EXAMINATION- Mitsubishi Polyester Film Gmbh, "Comparative data for plastic films", (20170101), pages 1 - 5, URL: www.m-petfilm.de, (20181009), XP055513578-
EXAMINATION- Perlen Packaging, "Perlalux duplex product overview", (20170101), pages 1 - 2, URL: www.perlenpackaging.com, (20181009), XP055513618-
EXAMINATION- Perlen Packaging, "Perlalux Tristar products overview", (20170101), URL: www.perlenpackaging.com, (20181009), XP055513590-
EXAMINATION- Voigt, "Kapitel 28", Pharmazeutische Technologie, (20100101), pages 630 - 634, XP055513587-
EXAMINATION- XP055513561-
EXAMINATION- RAMANAIAH CHENNURU ET AL, "Iso-Structurality Induced Solid Phase Transformations: A Case Study with Lenalidomide", CRYSTAL GROWTH & DESIGN., US, (20161230), vol. 17, no. 2, doi:10.1021/acs.cgd.6b01462, ISSN 1528-7483, pages 612 - 628, XP055513584
INTERNATIONAL-SEARCH-REPORT- CAIRA M R, "CRYSTALLINE POLYMORPHISM OF ORGANIC COMPOUNDS", TOPICS IN CURRENT CHEMISTRY, SPRINGER, BERLIN, DE, (19980101), vol. 198, doi:10.1007/3-540-69178-2_5, ISSN 0340-1022, ISBN 978-3-540-36760-4, pages 163 - 208, XP001156954 [Y] 1-13 * page 165 - page 166 *
INTERNATIONAL-SEARCH-REPORT- MARTIN H. BOLLI ET AL, "The Discovery of N -[5-(4-Bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]- N '-propylsulfamide (Macitentan), an Orally Active, Potent Dual Endothelin Receptor Antagonist", JOURNAL OF MEDICINAL CHEMISTRY, (20120913), vol. 55, no. 17, doi:10.1021/jm3009103, ISSN 0022-2623, pages 7849 - 7861, XP055078934 [A] 1-13 * Synthesis *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents